다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
영국
LSE
Roche Holding Ag (0QQ6)
Roche Holding Ag (0QQ6) 뉴스

0QQ6

Roche (0QQ6)

Roche Holding Ag

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:LSE:0QQ6

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/03/17	15:00	UK Regulatory	Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference	LSE:0QQ6	Roche Holding Ag
2025/03/12	15:00	UK Regulatory	Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity	LSE:0QQ6	Roche Holding Ag
2025/03/07	15:00	UK Regulatory	Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston	LSE:0QQ6	Roche Holding Ag
2025/03/05	15:00	UK Regulatory	FDA accepts supplemental Biologics License Application for Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis	LSE:0QQ6	Roche Holding Ag
2025/03/03	07:00	UK Regulatory	Phase III study shows Xolair may be more effective with fewer side effects than oral immunotherapy for the treatment of food allergies	LSE:0QQ6	Roche Holding Ag
2025/02/28	22:15	UK Regulatory	CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma	LSE:0QQ6	Roche Holding Ag
2025/02/21	03:30	UK Regulatory	Roche unveils a new class of next-generation sequencing with its novel sequencing by expansion technology	LSE:0QQ6	Roche Holding Ag
2025/02/13	01:45	UK Regulatory	FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)	LSE:0QQ6	Roche Holding Ag
2025/02/07	17:45	UK Regulatory	New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis	LSE:0QQ6	Roche Holding Ag
2025/02/05	01:45	UK Regulatory	FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness	LSE:0QQ6	Roche Holding Ag
2025/02/01	01:45	UK Regulatory	Roche receives FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU	LSE:0QQ6	Roche Holding Ag
2025/01/30	15:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth	LSE:0QQ6	Roche Holding Ag
2025/01/30	15:00	UK Regulatory	[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche erzielt starkes Jahresergebnis für 2024 mit Verkaufswachstum von 7%; drittes Quartal in Folge mit 9% Wachstum	LSE:0QQ6	Roche Holding Ag
2025/01/29	15:00	UK Regulatory	Change to the Roche Enlarged Corporate Executive Committee	LSE:0QQ6	Roche Holding Ag
2025/01/28	15:00	UK Regulatory	Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer	LSE:0QQ6	Roche Holding Ag
2025/01/27	15:00	UK Regulatory	Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)	LSE:0QQ6	Roche Holding Ag
2025/01/22	15:00	UK Regulatory	Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care	LSE:0QQ6	Roche Holding Ag
2025/01/08	15:10	UK Regulatory	Roche purchases shares in tender offer for Poseida Therapeutics, Inc.	LSE:0QQ6	Roche Holding Ag
2024/12/19	15:00	UK Regulatory	Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease	LSE:0QQ6	Roche Holding Ag
2024/12/18	15:00	UK Regulatory	Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution	LSE:0QQ6	Roche Holding Ag
2024/12/13	15:10	UK Regulatory	Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness	LSE:0QQ6	Roche Holding Ag
2024/12/13	15:00	UK Regulatory	Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities	LSE:0QQ6	Roche Holding Ag
2024/12/10	15:00	UK Regulatory	New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma	LSE:0QQ6	Roche Holding Ag
2024/12/10	06:30	UK Regulatory	Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash	LSE:0QQ6	Roche Holding Ag
2024/12/09	02:30	UK Regulatory	Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma	LSE:0QQ6	Roche Holding Ag
2024/12/05	15:00	UK Regulatory	FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma	LSE:0QQ6	Roche Holding Ag
2024/11/26	15:10	UK Regulatory	Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies	LSE:0QQ6	Roche Holding Ag
2024/11/26	15:00	UK Regulatory	Roche reports update on Phase III SKYSCRAPER-01 study results	LSE:0QQ6	Roche Holding Ag
2024/11/05	23:15	UK Regulatory	Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024	LSE:0QQ6	Roche Holding Ag
2024/10/31	15:15	UK Regulatory	Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease	LSE:0QQ6	Roche Holding Ag

검색 관련기사 보기:LSE:0QQ6

1 2 3 4 다음 >>

Societe Generale Effekten

KKR Acquisition Holdings I

Empire State Realty

Akoya BioSciences

Brookfield Renewable

God Bless America ETF

iShares US Digital Infra...

IT0005616336 20250602 8.25

Credit Suisse Ag London ...

Advanced Micro Devices

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관